Avanafil, a potent new selective phosphodiesterase type 5 （PDE5） inhibitor, has been developed for the treatment of erectile dysfunction （ED）. We carried out a systematic review and meta-analysis to assess the eff...Avanafil, a potent new selective phosphodiesterase type 5 （PDE5） inhibitor, has been developed for the treatment of erectile dysfunction （ED）. We carried out a systematic review and meta-analysis to assess the efficacy and safety of this drug for the treatment of ED. A literature review was performed to identify all published randomized, double-blind, placebo-controlled trials of avanafil for the treatment of ED. The search included the following databases： MEDLINE, EMBASE and the Cochrane Controlled Trials Register. The reference lists of the retrieved studies were also investigated. Four publications, involving a total of 1381 patients, were used in the analysis, including four randomized controlled trials （RCTs） that compared avanafU with a placebo. Among the co-primary efficacy end points indicating that avanafil 100 mg was more effective than a placebo were successful vaginal penetration （SEP2） （the odds ratio （OR） =5.06, 95% confidence interval （CI） =3.29-7.78, P〈 0.00001） and successful intercourse （SEP3） （OR = 3.99, 95% CI = 2.80-5.67, P 〈 0.00001）. Men randomized to receive avanafil were less likely than those receiving the placebo to drop out due to an adverse event （AE） （OR = 1.48, 95% CI = 0.54-4.08, P = 0.44）. Specific AEs with avanafil included headache and flushing, which were significantly less likely to occur with placebo. This meta-analysis indicates that avanafil 100 or 200 mg is an effective and well-tolerated treatment for ED. Compared with avanafil 100 mg, patients who take avanafil 200 mg are more likely to experience headaches.展开更多
以4-(3-氯-4-甲氧基苄基氨基)-2-[(2S)-2-羟甲基-1-吡咯烷基]-5-嘧啶羧酸乙酯为原料,合成了4-(3-氯-4-甲氧基苄基氨基)-2-[(2S)-2-羟甲基-1-吡咯烷基]-N-(2-吡啶甲基)-5-嘧啶甲酰胺,研究了此种阿伐那非类似物的合成条件优化,考察了投料...以4-(3-氯-4-甲氧基苄基氨基)-2-[(2S)-2-羟甲基-1-吡咯烷基]-5-嘧啶羧酸乙酯为原料,合成了4-(3-氯-4-甲氧基苄基氨基)-2-[(2S)-2-羟甲基-1-吡咯烷基]-N-(2-吡啶甲基)-5-嘧啶甲酰胺,研究了此种阿伐那非类似物的合成条件优化,考察了投料比、反应温度、反应时间等因素对产率的影响.获得较高产率的反应条件为n(C6H8N2)∶n(C18H21ClN4O4)∶n(EDCI)∶n(HOBt)∶n(Et3N)=1.2∶1∶1.2∶1.2∶2,在搅拌下,60℃反应6h,经过后处理,柱层析纯化,得到类白色固体产物,产率为84.3%.所合成的产物经FT-IR、1 H NMR、13 C NMR、ESI-MS得到验证.展开更多
文摘Avanafil, a potent new selective phosphodiesterase type 5 （PDE5） inhibitor, has been developed for the treatment of erectile dysfunction （ED）. We carried out a systematic review and meta-analysis to assess the efficacy and safety of this drug for the treatment of ED. A literature review was performed to identify all published randomized, double-blind, placebo-controlled trials of avanafil for the treatment of ED. The search included the following databases： MEDLINE, EMBASE and the Cochrane Controlled Trials Register. The reference lists of the retrieved studies were also investigated. Four publications, involving a total of 1381 patients, were used in the analysis, including four randomized controlled trials （RCTs） that compared avanafU with a placebo. Among the co-primary efficacy end points indicating that avanafil 100 mg was more effective than a placebo were successful vaginal penetration （SEP2） （the odds ratio （OR） =5.06, 95% confidence interval （CI） =3.29-7.78, P〈 0.00001） and successful intercourse （SEP3） （OR = 3.99, 95% CI = 2.80-5.67, P 〈 0.00001）. Men randomized to receive avanafil were less likely than those receiving the placebo to drop out due to an adverse event （AE） （OR = 1.48, 95% CI = 0.54-4.08, P = 0.44）. Specific AEs with avanafil included headache and flushing, which were significantly less likely to occur with placebo. This meta-analysis indicates that avanafil 100 or 200 mg is an effective and well-tolerated treatment for ED. Compared with avanafil 100 mg, patients who take avanafil 200 mg are more likely to experience headaches.
文摘以4-(3-氯-4-甲氧基苄基氨基)-2-[(2S)-2-羟甲基-1-吡咯烷基]-5-嘧啶羧酸乙酯为原料,合成了4-(3-氯-4-甲氧基苄基氨基)-2-[(2S)-2-羟甲基-1-吡咯烷基]-N-(2-吡啶甲基)-5-嘧啶甲酰胺,研究了此种阿伐那非类似物的合成条件优化,考察了投料比、反应温度、反应时间等因素对产率的影响.获得较高产率的反应条件为n(C6H8N2)∶n(C18H21ClN4O4)∶n(EDCI)∶n(HOBt)∶n(Et3N)=1.2∶1∶1.2∶1.2∶2,在搅拌下,60℃反应6h,经过后处理,柱层析纯化,得到类白色固体产物,产率为84.3%.所合成的产物经FT-IR、1 H NMR、13 C NMR、ESI-MS得到验证.
